BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 24022278)

  • 21. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.
    Luttikhuis ME; Powell JE; Rees SA; Genus T; Chughtai S; Ramani P; Mann JR; McConville CM
    Br J Cancer; 2001 Aug; 85(4):531-7. PubMed ID: 11506492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of chromogenic in situ hybridization to identify MYCN gene copy number in neuroblastoma using routine tissue sections.
    Thorner PS; Ho M; Chilton-MacNeill S; Zielenska M
    Am J Surg Pathol; 2006 May; 30(5):635-42. PubMed ID: 16699319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
    Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
    Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics.
    Jeison M; Ash S; Halevy-Berko G; Mardoukh J; Luria D; Avigad S; Feinberg-Gorenshtein G; Goshen Y; Hertzel G; Kapelushnik J; Ben Barak A; Attias D; Steinberg R; Stein J; Stark B; Yaniv I
    Am J Pathol; 2010 Jun; 176(6):2616-25. PubMed ID: 20395439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay.
    De Preter K; Speleman F; Combaret V; Lunec J; Laureys G; Eussen BH; Francotte N; Board J; Pearson AD; De Paepe A; Van Roy N; Vandesompele J
    Mod Pathol; 2002 Feb; 15(2):159-66. PubMed ID: 11850545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rearrangement in the coding region of the MYCN gene in a subset of amplicons in a case of neuroblastoma with MYCN amplification.
    Chen B; Jhanwar SC; Ladanyi M
    Diagn Mol Pathol; 2001 Jun; 10(2):100-4. PubMed ID: 11385318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of MYCN status on response of high-risk neuroblastoma to neoadjuvant chemotherapy.
    Yanishevski D; McCarville MB; Doubrovin M; Spiegl HR; Zhao X; Lu Z; Federico SM; Furman WL; Murphy AJ; Davidoff AM
    J Pediatr Surg; 2020 Jan; 55(1):130-134. PubMed ID: 31685267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
    Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
    J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
    Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
    Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification.
    Raschellà G; Cesi V; Amendola R; Negroni A; Tanno B; Altavista P; Tonini GP; De Bernardi B; Calabretta B
    Cancer Res; 1999 Jul; 59(14):3365-8. PubMed ID: 10416595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative real-time PCR for quick simultaneous determination of therapy-stratifying markers MYCN amplification, deletion 1p and 11q.
    Boensch M; Oberthuer A; Fischer M; Skowron M; Oestreich J; Berthold F; Spitz R
    Diagn Mol Pathol; 2005 Sep; 14(3):177-82. PubMed ID: 16106200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant p53 mutation and MYCN amplification in neuroblastoma.
    Manhani R; Cristofani LM; Odone Filho V; Bendit I
    Med Pediatr Oncol; 1997 Sep; 29(3):206-7. PubMed ID: 9212845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between the number of segmental chromosome aberrations and the age at diagnosis of diploid neuroblastomas without MYCN amplification.
    Souzaki R; Tajiri T; Teshiba R; Kinoshita Y; Yosue R; Kohashi K; Oda Y; Taguchi T
    J Pediatr Surg; 2011 Dec; 46(12):2228-32. PubMed ID: 22152855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of neuroblastoma stage on serum-based detection of MYCN amplification.
    Combaret V; Hogarty MD; London WB; McGrady P; Iacono I; Brejon S; Swerts K; Noguera R; Gross N; Rousseau R; Puisieux A
    Pediatr Blood Cancer; 2009 Sep; 53(3):329-31. PubMed ID: 19301388
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating MYCN DNA predicts MYCN-amplification in neuroblastoma.
    Combaret V; Bergeron C; Noguera R; Iacono I; Puisieux A
    J Clin Oncol; 2005 Dec; 23(34):8919-20; author reply 8920. PubMed ID: 16314658
    [No Abstract]   [Full Text] [Related]  

  • 37. Expression of P27(KIP1) is prognostic and independent of MYCN amplification in human neuroblastoma.
    Bergmann E; Wanzel M; Weber A; Shin I; Christiansen H; Eilers M
    Int J Cancer; 2001 May; 95(3):176-83. PubMed ID: 11307151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
    Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR.
    Souzaki R; Tajiri T; Higashi M; Kinoshita Y; Tanaka S; Kohashi K; Tsuneyoshi M; Taguchi T
    Pediatr Surg Int; 2008 Oct; 24(10):1095-100. PubMed ID: 18726105
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorescence in situ hybridization (FISH) detection of MYCN oncogene amplification in neuroblastoma using paraffin-embedded tissues.
    Misra DN; Dickman PS; Yunis EJ
    Diagn Mol Pathol; 1995 Jun; 4(2):128-35. PubMed ID: 7551293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.